Update on Trelstar Safety Information and Regulatory Background

The U.S. Food and Drug Administration (FDA) has completed its review and approved updates to the safety label for Trelstar (triptorelin pamoate), a prostate cancer treatment marketed by Verity Pharmaceuticals. This amendment includes the addition of specific warnings regarding severe cutaneous adverse reactions (SCAR) and systemic convulsions, aiming to enhance the safe prescribing of the medication. Originally approved by the FDA in June 2000, Trelstar is a leading gonadotropin-releasing hormone (GnRH) agonist used in androgen deprivation therapy (ADT) for prostate cancer patients. In 2020, Verity entered into a 20-year exclusive commercialization agreement with Debiopharm, securing U.S. marketing rights, and has since focused on ongoing safety monitoring and incorporating regulatory changes to extend the product's lifecycle.

Competitive Landscape in the Prostate Cancer Hormone Therapy Market

The ADT market, which includes Trelstar, has been dominated for decades by AbbVie's Lupron (leuprolide) and AstraZeneca's Zoladex (goserelin). Recently, new oral GnRH antagonists, such as Pfizer's Orgovyx (relugolix), which offer the advantage of no initial testosterone flare and ease of administration, have emerged, putting pressure on the established injectable treatments. In response, existing injectable GnRH agonists are strengthening their depot formulations with various administration schedules (1-month, 3-month, 6-month) to improve convenience and patient compliance, thereby defending their market share.

Growth Potential and Commercial Value of the Global GnRH Market

The global GnRH agonist market is estimated at approximately $6.8 billion (approximately 9 trillion KRW) in 2025, with prostate cancer accounting for over 38% of this market. With the aging population and the increasing number of new prostate cancer patients each year, the global demand for hormone therapies is expected to continue to grow at a compound annual growth rate (CAGR) of approximately 5.8% through 2034.

Although Trelstar is an older drug nearing the end of its patent life, it remains a trusted treatment for patients with metastatic and progressive prostate cancer and continues to be a stable revenue generator in Verity's pipeline.

Impact of the Label Amendment on Prescribing Patterns and the Market

The updated safety information is seen as a tool to help healthcare professionals identify and manage potential risks during treatment. While the addition of warnings about severe skin reactions and convulsions may lead to more cautious prescribing in the short term, the transparent sharing of safety data will ultimately enhance the product's credibility. In particular, the rapid update of the adverse event profile in a complex regulatory environment provides a competitive advantage in terms of legal and commercial risk management, which will be beneficial for long-term market share defense.